{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:35:55Z","timestamp":1789644955779,"version":"4.0.0"},"reference-count":124,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prostate cancer (PCa) is one of the most common malignancies in men, and metastatic castration-resistant PCa (mCRPC) has limited treatment options. While chimeric antigen receptor T (CAR-T) therapy has revolutionized treatment of hematologic cancers, its efficacy in PCa is constrained by factors such as scarce tumor-specific antigens, an immunosuppressive tumor microenvironment (TME), antigen heterogeneity, and safety issues (e.g., cytokine release syndrome).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a comprehensive literature review of CAR-T therapy in PCa. We summarized known PCa-specific CAR targets, identified major TME-related and technical barriers, and highlighted recent advances in CAR engineering (including armored CAR-T cells, gene editing, and metabolic reprogramming) as well as combination approaches with other therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Emerging strategies show promise for overcoming these obstacles. Next-generation CAR designs, such as cytokine-armed CAR-T cells, may enhance T cell infiltration and persistence despite the suppressive TME. Modulating tumor metabolism and immune checkpoints can reverse T cell exhaustion. Multi-antigen CARs and targeted gene edits (for example, PD-1 disruption) may limit antigen escape. Early clinical trials in PCa have demonstrated CAR-T cells specifically recognizing prostate-associated antigens and eliciting antitumor immune responses, although durable remissions remain rare.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CAR-T therapy for prostate cancer is a rapidly advancing field. This review provides an updated perspective on CAR-T targets, engineering strategies, and combination approaches in PCa. Ongoing innovations in CAR design and therapeutic combinations offer the potential to develop more effective and durable CAR-T treatments for advanced prostate cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1659869","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T05:33:54Z","timestamp":1770183234000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Advancing CAR-T therapy in prostate cancer: overcoming the tumor microenvironment and enhancing efficacy"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhongze","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Urology, Second Hospital of Lanzhou University","place":["Lanzhou, Gansu, China"]},{"name":"The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongfeng","family":"Lao","sequence":"additional","affiliation":[{"name":"Department of Urology, Second Hospital of Lanzhou University","place":["Lanzhou, Gansu, China"]},{"name":"The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Urology, Second Hospital of Lanzhou University","place":["Lanzhou, Gansu, China"]},{"name":"The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Urology, Second Hospital of Lanzhou University","place":["Lanzhou, Gansu, China"]},{"name":"The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Urology, Second Hospital of Lanzhou University","place":["Lanzhou, Gansu, China"]},{"name":"The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxuan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, Second Hospital of Lanzhou University","place":["Lanzhou, Gansu, China"]},{"name":"The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, Second Hospital of Lanzhou University","place":["Lanzhou, Gansu, China"]},{"name":"The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangbin","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Urology, Second Hospital of Lanzhou University","place":["Lanzhou, Gansu, China"]},{"name":"The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhilong","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Urology, Second Hospital of Lanzhou University","place":["Lanzhou, Gansu, China"]},{"name":"The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA A Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2021.06.010","article-title":"The treatment landscape of metastatic prostate cancer","volume":"519","author":"Yamada","year":"2021","journal-title":"Cancer Letters"},{"key":"B3","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.tmrv.2019.01.005","article-title":"Risks and benefits of chimeric antigen receptor T-cell (CAR-T) therapy in cancer: A systematic review and meta-analysis","volume":"33","author":"Grigor","year":"2019","journal-title":"Transfusion Med Rev"},{"key":"B4","doi-asserted-by":"publisher","first-page":"101437","DOI":"10.1016\/j.smim.2020.101437","article-title":"Adoptive T cell therapy: Boosting the immune system to fight cancer","volume":"49","author":"Leon","year":"2020","journal-title":"Semin Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Cancer Network"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.07.002","article-title":"CAR T cell combination therapies to treat cancer","volume":"42","author":"Uslu","year":"2024","journal-title":"Cancer Cell"},{"key":"B8","doi-asserted-by":"publisher","first-page":"100826","DOI":"10.1016\/j.currproblcancer.2021.100826","article-title":"CAR T-cell therapy for B-cell lymphoma","volume":"46","author":"Denlinger","year":"2022","journal-title":"Curr Problems Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.927153","article-title":"CAR-T cell therapy in hematological Malignancies: Current opportunities and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"103941","DOI":"10.1016\/j.ebiom.2022.103941","article-title":"Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion","volume":"77","author":"Gumber","year":"2022","journal-title":"eBioMedicine"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30040323","article-title":"Metastatic castration-resistant prostate cancer, immune checkpoint inhibitors, and beyond","volume":"30","author":"Lanka","year":"2023","journal-title":"Curr Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02979-8","article-title":"PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: A phase 1 trial","volume":"30","author":"Dorff","year":"2024","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2015.12.022","article-title":"Regulation of prostate cancer progression by the tumor microenvironment","volume":"380","author":"Shiao","year":"2016","journal-title":"Cancer Letters"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.744823","article-title":"Advances in universal CAR-T cell therapy","volume":"12","author":"Lin","year":"2021","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3390\/biom10020263","article-title":"Recent advances in allogeneic CAR-T cells","volume":"10","author":"Kim","year":"2020","journal-title":"Biomolecules"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S185556","article-title":"CART cell therapy for prostate cancer: Status and promise","volume":"12","author":"Yu","year":"2019","journal-title":"OTT"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12131","article-title":"Design and development of therapies using chimeric antigen receptor-expressing T cells","volume":"257","author":"Dotti","year":"2014","journal-title":"Immunol Rev"},{"key":"B18","doi-asserted-by":"publisher","first-page":"16014","DOI":"10.1038\/mto.2016.14","article-title":"CAR models: Next-generation CAR modifications for enhanced T-cell function","volume":"3","author":"Abate-Daga","year":"2016","journal-title":"Mol Ther - Oncolytics"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discovery"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: The fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0376","article-title":"Transgenic expression of IL15 improves antiglioma activity of IL13R\u03b12-CAR T cells but results in antigen loss variants","volume":"5","author":"Krenciute","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK\u2013STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"16015","DOI":"10.1038\/mto.2016.15","article-title":"Clinical manufacturing of CAR T cells: Foundation of a promising therapy","volume":"3","author":"Wang","year":"2016","journal-title":"Mol Ther - Oncolytics"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce antitumor activity in solid Malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1172\/JCI86721","article-title":"Phase I trials using sleeping beauty to generate CD19-specific CAR T cells","volume":"126","author":"Kebriaei","year":"2016","journal-title":"J Clin Invest"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci Transl Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201607485","article-title":"Clinical development of CAR T cells\u2014challenges and opportunities in translating innovative treatment concepts","volume":"9","author":"Hartmann","year":"2017","journal-title":"EMBO Mol Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-023-00725-8","article-title":"Real-world treatment patterns and overall survival among men with metastatic castration-resistant prostate cancer (mCRPC) in the US medicare population","volume":"27","author":"Freedland","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1080\/21681805.2020.1739139","article-title":"Survival in patients diagnosed with castration-resistant prostate cancer: A population-based observational study in Sweden","volume":"54","author":"Aly","year":"2020","journal-title":"Scandinavian J Urol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12943-024-02137-1","article-title":"Prostate cancer microenvironment: Multidimensional regulation of immune cells, vascular system, stromal cells, and microbiota","volume":"23","author":"Chen","year":"2024","journal-title":"Mol Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1126752","article-title":"Progression in immunotherapy for advanced prostate cancer","volume":"13","author":"Liang","year":"2023","journal-title":"Front Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2014.03.004","article-title":"Tumor microenvironment and metabolism in prostate cancer","volume":"41","author":"Chiarugi","year":"2014","journal-title":"Semin Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"110240","DOI":"10.1016\/j.cellsig.2021.110240","article-title":"Activation of TGF-\u03b2 - SMAD2 signaling by IL-6 drives neuroendocrine differentiation of prostate cancer through p38MAPK","volume":"91","author":"Natani","year":"2022","journal-title":"Cell Signaling"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.3390\/cancers12092382","article-title":"Angiogenesis inhibition in prostate cancer: An update","volume":"12","author":"Sarkar","year":"2020","journal-title":"Cancers"},{"key":"B35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40880-017-0198-3","article-title":"Immune mediators in the tumor microenvironment of prostate cancer","volume":"36","author":"Dai","year":"2017","journal-title":"Chin J Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0045(20000901)44:4<271::AID-PROS2>3.0.CO;2-G","article-title":"Analysis of type T1 and T2 cytokines in patients with prostate cancer","volume":"44","author":"Filella","year":"2000","journal-title":"Prostate"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2013.465","article-title":"Inhibition of cell migration and invasion mediated by the TAT-RasGAP317\u2013326 peptide requires the DLC1 tumor suppressor","volume":"33","author":"Barras","year":"2014","journal-title":"Oncogene"},{"key":"B38","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/s41467-021-21245-w","article-title":"Plasma cells are enriched in localized prostate cancer in black men and are associated with improved outcomes","volume":"12","author":"Weiner","year":"2021","journal-title":"Nat Commun"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumor-associated macrophages inhibits phagocytosis and tumor immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133977","article-title":"TGF-\u03b2 inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors","volume":"5","author":"Tang","year":"2020","journal-title":"JCI Insight"},{"key":"B41","article-title":"Dominant uptake of fatty acid over glucose by prostate cells: A potential new diagnostic and therapeutic approach","volume":"30","author":"Liu","year":"2010","journal-title":"Anticancer Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/cells11010020","article-title":"Myeloid-derived suppressor cells in prostate cancer: Present knowledge and future perspectives","volume":"11","author":"Koinis","year":"2021","journal-title":"Cells"},{"key":"B43","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3390\/ijms20010098","article-title":"IL-8 secreted from M2 macrophages promoted prostate tumorigenesis via STAT3\/MALAT1 pathway","volume":"20","author":"Zheng","year":"2018","journal-title":"IJMS"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20210564","article-title":"Lipid-loaded tumor-associated macrophages sustain tumor growth and invasiveness in prostate cancer","volume":"219","author":"Masetti","year":"2022","journal-title":"J Exp Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2013.09.007","article-title":"Origins of metastatic traits","volume":"24","author":"Vanharanta","year":"2013","journal-title":"Cancer Cell"},{"key":"B46","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.ccell.2019.05.003","article-title":"Symbiotic macrophage-glioma cell interactions reveal synthetic lethality in PTEN-null glioma","volume":"35","author":"Chen","year":"2019","journal-title":"Cancer Cell"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1136\/jitc\u20112021\u2011003776","article-title":"Phase I\/II study of the LAG-3 inhibitor ieramilimab (LAG525) \u00b1 anti-PD-1 spartalizumab (PDR001) in patients with advanced Malignancies","volume":"10","author":"Sch\u00f6ffski","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B48","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nature14424","article-title":"Allogeneic IgG combined with dendritic cell stimuli induce antitumor T-cell immunity","volume":"521","author":"Carmi","year":"2015","journal-title":"Nature"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3892\/or.2020.7731","article-title":"MicroRNA\u2212188\u22125p inhibits the progression of breast cancer by targeting zinc finger protein 91","volume":"44","author":"Yang","year":"2020","journal-title":"Oncol Rep"},{"key":"B50","doi-asserted-by":"publisher","first-page":"4503","DOI":"10.3390\/nu13124503","article-title":"Arginine and arginases modulate metabolism, tumor microenvironment and prostate cancer progression","volume":"13","author":"Matos","year":"2021","journal-title":"Nutrients"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.1012112","article-title":"C1QBP regulates mitochondrial plasticity to impact tumor progression and antitumor immune response","volume":"13","author":"Wang","year":"2022","journal-title":"Front Physiol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/nature17412","article-title":"Potentiating the antitumor response of CD8+ T cells by modulating cholesterol metabolism","volume":"531","author":"Yang","year":"2016","journal-title":"Nature"},{"key":"B53","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41590-019-0589-5","article-title":"CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors","volume":"21","author":"Wang","year":"2020","journal-title":"Nat Immunol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/j.cmet.2022.08.017","article-title":"OMA1-mediated integrated stress response protects against ferroptosis in mitochondrial cardiomyopathy","volume":"34","author":"Ahola","year":"2022","journal-title":"Cell Metab"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23883","article-title":"A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer","volume":"79","author":"Paller","year":"2019","journal-title":"Prostate"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00040","article-title":"Hypoxia pathway proteins as central mediators of metabolism in the tumor cells and their microenvironment","volume":"9","author":"Sormendi","year":"2018","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0299","article-title":"Single-cell analysis reveals EP4 as a target for restoring T-cell infiltration and sensitizing prostate cancer to immunotherapy","volume":"28","author":"Peng","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3724\/abbs.2023092","article-title":"Advances in landscape and related therapeutic targets of the prostate tumor microenvironment","volume":"55","author":"Li","year":"2023","journal-title":"ABBS"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2024.2380894","article-title":"CAR-T cell technologies that interact with the tumor microenvironment in solid tumors","volume":"20","author":"Taylor","year":"2024","journal-title":"Expert Rev Clin Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1002\/pros.21134","article-title":"Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice","volume":"70","author":"Arredouani","year":"2010","journal-title":"Prostate"},{"key":"B61","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3390\/cancers4010193","article-title":"Tumor-associated antigens for specific immunotherapy of prostate cancer","volume":"4","author":"Kiessling","year":"2012","journal-title":"Cancers"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR\u03b6\/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat Biotechnol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0436","article-title":"Targeted elimination of prostate cancer by genetically directed human T lymphocytes","volume":"65","author":"Gade","year":"2005","journal-title":"Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0109427","article-title":"PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models","volume":"9","author":"Zuccolotto","year":"2014","journal-title":"PLoS One"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Mol Ther"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2020.06.014","article-title":"PSMA-directed CAR T cells combined with low-dose docetaxel treatment induce tumor regression in a prostate cancer xenograft model","volume":"18","author":"Alzubi","year":"2020","journal-title":"Mol Ther - Oncolytics"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23214","article-title":"Phase I trial of anti-PSMA designer CAR-T cells in prostate cancer: Possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical response","volume":"76","author":"Junghans","year":"2016","journal-title":"Prostate"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.6_suppl.098","article-title":"Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"40","author":"Slovin","year":"2022","journal-title":"JCO"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.4161\/cam.18953","article-title":"EpCAM and its potential role in tumor-initiating cells","volume":"6","author":"Imrich","year":"2012","journal-title":"Cell Adhesion Migration"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1186\/s12885-018-5010-5","article-title":"Epithelial cell adhesion molecule (EpCAM) is involved in prostate cancer chemotherapy\/radiotherapy response in vivo","volume":"18","author":"Ni","year":"2018","journal-title":"BMC Cancer"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12865-014-0064-x","article-title":"Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM","volume":"16","author":"Deng","year":"2015","journal-title":"BMC Immunol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1806009","DOI":"10.1080\/2162402X.2020.1806009","article-title":"Potential lung attack and lethality generated by EpCAM-specific CAR-T cells in immunocompetent mouse models","volume":"9","author":"Qin","year":"2020","journal-title":"OncoImmunology"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602924","article-title":"Frequent high-level expression of the immunotherapeutic target ep-CAM in colon, stomach, prostate and lung cancers","volume":"94","author":"Went","year":"2006","journal-title":"Br J Cancer"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg9721","article-title":"EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors","volume":"9","author":"Li","year":"2023","journal-title":"Sci Adv"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(11)60154-7","article-title":"Re: Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"185","author":"Walsh","year":"2011","journal-title":"J Urol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s40425-019-0741-7","article-title":"CAR-T cell therapy: A potential new strategy against prostate cancer","volume":"7","author":"Schepisi","year":"2019","journal-title":"J immunother cancer"},{"key":"B78","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3390\/ijms22020640","article-title":"Chimeric antigen receptor-engineered T cell therapy for the management of patients with metastatic prostate cancer: A comprehensive review","volume":"22","author":"Yu","year":"2021","journal-title":"IJMS"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203426","article-title":"Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer","volume":"19","author":"Gu","year":"2000","journal-title":"Oncogene"},{"key":"B80","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1471-2407-14-30","article-title":"Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice","volume":"14","author":"Hillerdal","year":"2014","journal-title":"BMC Cancer"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1380764","article-title":"Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer","volume":"7","author":"Priceman","year":"2018","journal-title":"OncoImmunology"},{"key":"B82","doi-asserted-by":"publisher","first-page":"111339","DOI":"10.1016\/j.biopha.2021.111339","article-title":"ShRNA-mediated silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft","volume":"137","author":"Zhou","year":"2021","journal-title":"Biomedicine Pharmacother"},{"key":"B83","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1038\/s41467-023-37874-2","article-title":"Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy","volume":"14","author":"Bhatia","year":"2023","journal-title":"Nat Commun"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2025.05.007","article-title":"STEAP1: A promising target in prostate cancer therapy","volume":"11","author":"Singh","year":"2025","journal-title":"Trends Cancer"},{"key":"B85","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.omto.2022.06.007","article-title":"Development of STEAP1 targeting chimeric antigen receptor for adoptive cell therapy against cancer","volume":"26","author":"Jin","year":"2022","journal-title":"Mol Ther - Oncolytics"},{"key":"B86","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s12032-018-1100-0","article-title":"Knockdown of STEAP1 inhibits cell growth and induces apoptosis in LNCaP prostate cancer cells counteracting the effect of androgens","volume":"35","author":"Gomes","year":"2018","journal-title":"Med Oncol"},{"key":"B87","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-025-01508-3","article-title":"Collagen-binding IL-12-armoured STEAP1 CAR-T cells reduce toxicity and treat prostate cancer in mouse models","author":"Sasaki","year":"2025","journal-title":"Nat BioMed Eng"},{"key":"B88","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41698-022-00323-2","article-title":"Integrative molecular analyses define correlates of high B7-H3 expression in metastatic castrate-resistant prostate cancer","volume":"6","author":"Shi","year":"2022","journal-title":"NPJ Precis Onc"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2024.05.003","article-title":"B7-H3: A robust target for immunotherapy in prostate cancer","volume":"10","author":"Pulido","year":"2024","journal-title":"Trends Cancer"},{"key":"B90","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41420-023-01453-7","article-title":"B7-H3 specific CAR-T cells exhibit potent activity against prostate cancer","volume":"9","author":"Li","year":"2023","journal-title":"Cell Death Discov"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13834","article-title":"Elevated expression of EPHA2 is associated with poor prognosis after radical prostatectomy in prostate cancer","volume":"39","author":"Kurose","year":"2019","journal-title":"Anticancer Res"},{"key":"B92","doi-asserted-by":"publisher","first-page":"102111","DOI":"10.1016\/j.tranon.2024.102111","article-title":"EphA2 specific chimeric antigen receptor engineered T cells for the treatment of prostate cancer","volume":"50","author":"Zhang","year":"2024","journal-title":"Transl Oncol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13045-020-00944-9","article-title":"Targeting Epha2 in cancer","volume":"13","author":"Xiao","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00678","article-title":"Pasritamig, a first-in-class, bispecific T-cell engager targeting human kallikrein 2, in metastatic castration-resistant prostate cancer: A phase I study","volume":"43","author":"Stein","year":"2025","journal-title":"JCO"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: A phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat Med"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.3390\/cells9061382","article-title":"Anti-PSMA CAR-engineered NK-92 cells: An off-the-shelf cell therapy for prostate cancer","volume":"9","author":"Montagner","year":"2020","journal-title":"Cells"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.901","article-title":"Combined treatment with anti-PSMA CAR NK-92 cell and anti-PD-L1 monoclonal antibody enhances the antitumor efficacy against castration-resistant prostate cancer","volume":"12","author":"Wang","year":"2022","journal-title":"Clin Trans Med"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03495-z","article-title":"CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: A phase 1 trial","volume":"31","author":"Reiss","year":"2025","journal-title":"Nat Med"},{"key":"B101","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41467-024-55770-1","article-title":"Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models","volume":"16","author":"Pierini","year":"2025","journal-title":"Nat Commun"},{"key":"B102","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13045-025-01743-w","article-title":"PSMA-targeted CAR-macrophages drive glycolytic reprogramming for enhanced prostate cancer immunotherapy","volume":"18","author":"Xu","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"JCO"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00607-3","article-title":"Preparing for CAR T cell therapy: Patient selection, bridging therapies and lymphodepletion","volume":"19","author":"Amini","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"16011","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol Ther - Oncolytics"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor\u2013modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplantation"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1739","article-title":"Itacitinib (INCB039110), a JAK1 inhibitor, reduces cytokines associated with cytokine release syndrome induced by CAR T-cell therapy","volume":"26","author":"Huarte","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.01.012","article-title":"Engineering customized cell sensing and response behaviors using synthetic notch receptors","volume":"164","author":"Morsut","year":"2016","journal-title":"Cell"},{"key":"B110","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41408-020-00405-z","article-title":"Preclinical development of CD126 CAR-T cells with broad antitumor activity","volume":"11","author":"Mishra","year":"2021","journal-title":"Blood Cancer J"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision tumor recognition by T cells with combinatorial antigen-sensing circuits","volume":"164","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: A phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat Med"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401710","article-title":"Coexpressed catalase protects chimeric antigen receptor\u2013redirected T cells as well as bystander cells from oxidative stress\u2013induced loss of antitumor activity","volume":"196","author":"Ligtenberg","year":"2016","journal-title":"J Immunol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2020.1739952","article-title":"Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression","volume":"21","author":"Weimin","year":"2020","journal-title":"Cancer Biol Ther"},{"key":"B116","doi-asserted-by":"publisher","first-page":"110807","DOI":"10.1016\/j.intimp.2023.110807","article-title":"Dominant negative TGF\u03b2 receptor II and truncated TIM3 enhance the antitumor efficacy of CAR-T-cell therapy in prostate cancer","volume":"124","author":"Tang","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.06.015","article-title":"LIGHT\/TNFSF14 promotes CAR-T cell trafficking and cytotoxicity through reversing immunosuppressive tumor microenvironment","volume":"31","author":"Zhang","year":"2023","journal-title":"Mol Ther"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn7336","article-title":"BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion","volume":"14","author":"Jung","year":"2022","journal-title":"Sci Transl Med"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-1319","article-title":"Disruption of SUV39H1 -mediated H3K9 methylation sustains CAR T-cell function","volume":"14","author":"Jain","year":"2024","journal-title":"Cancer Discovery"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0064","article-title":"The interplay of immunotherapy and chemotherapy: Harnessing potential synergies","volume":"3","author":"Emens","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B121","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.omto.2016.11.005","article-title":"Enhancement of PSMA-directed CAR adoptive immunotherapy by PD-1\/PD-L1 blockade","volume":"4","author":"Serganova","year":"2017","journal-title":"Mol Ther - Oncolytics"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.09.006","article-title":"Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors","volume":"36","author":"Grosser","year":"2019","journal-title":"Cancer Cell"},{"key":"B123","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.3390\/cancers14071696","article-title":"Upregulation of PSMA expression by enzalutamide in patients with advanced mCRPC","volume":"14","author":"Rosar","year":"2022","journal-title":"Cancers"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/jamaoncol.2021.0168","article-title":"Radiotherapy to enhance chimeric antigen receptor T-cell therapeutic efficacy in solid tumors: A narrative review","volume":"7","author":"Hauth","year":"2021","journal-title":"JAMA Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1659869\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:55:39Z","timestamp":1771926939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1659869\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":124,"alternative-id":["10.3389\/fonc.2026.1659869"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1659869","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"article-number":"1659869"}}